Success Metrics

Clinical Success Rate
78.1%

Based on 57 completed trials

Completion Rate
78%(57/73)
Active Trials
16(14%)
Results Posted
54%(31 trials)
Terminated
16(14%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_1
37
32%
Ph phase_2
61
53%
Ph phase_3
7
6%
Ph phase_4
5
4%
Ph not_applicable
5
4%

Phase Distribution

38

Early Stage

61

Mid Stage

12

Late Stage

Phase Distribution116 total trials
Early Phase 1First-in-human
1(0.9%)
Phase 1Safety & dosage
37(31.9%)
Phase 2Efficacy & side effects
61(52.6%)
Phase 3Large-scale testing
7(6.0%)
Phase 4Post-market surveillance
5(4.3%)
N/ANon-phased studies
5(4.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.1%

57 of 78 finished

Non-Completion Rate

26.9%

21 ended early

Currently Active

16

trials recruiting

Total Trials

116

all time

Status Distribution
Active(21)
Completed(57)
Terminated(21)
Other(17)

Detailed Status

Completed57
unknown17
Terminated16
Active, not recruiting9
Recruiting7
Withdrawn5

Development Timeline

Analytics

Development Status

Total Trials
116
Active
16
Success Rate
78.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.9%)
Phase 137 (31.9%)
Phase 261 (52.6%)
Phase 37 (6.0%)
Phase 45 (4.3%)
N/A5 (4.3%)

Trials by Status

withdrawn54%
terminated1614%
active_not_recruiting98%
completed5749%
recruiting76%
not_yet_recruiting54%
unknown1715%

Recent Activity

Clinical Trials (116)

Showing 20 of 116 trialsScroll for more
NCT01857934Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Completed
NCT05266001Phase 3

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Completed
NCT06450041Phase 2

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Recruiting
NCT04936529Phase 2

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Recruiting
NCT04238819Phase 1

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Completed
NCT07377435Phase 1

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Not Yet Recruiting
NCT07374029Phase 1

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Not Yet Recruiting
NCT05544968Phase 1

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Not Yet Recruiting
NCT07327411Phase 2

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Not Yet Recruiting
NCT05307835Phase 1

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Active Not Recruiting
NCT03630211Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting
NCT03033303Phase 2

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Completed
NCT02502786Phase 2

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active Not Recruiting
NCT04229979Phase 3

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active Not Recruiting
NCT06799026Phase 1

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Recruiting
NCT03189706Early Phase 1

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active Not Recruiting
NCT06013618Phase 2

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Recruiting
NCT00661622Phase 2

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Completed
NCT03600350Phase 2

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active Not Recruiting
NCT01903330Phase 2

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Active Not Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
116